Drug efficacy evaluation in bone metastasis models

Introduction

This new White Paper from Pharmatest, ‘Drug efficacy evaluation in bone metastasis models – Why and How?’ highlights the importance of studying drug efficacy in bone metastasis models. Bone microenvironment often provides drug resistance to the tumor and drugs that efficiently kill the tumor when it is outside the bone may be ineffective when the tumor gets in the bone. This may lead to ineffective compounds entering clinical trials in cancers that commonly develop bone metastases, such as breast and prostate cancer. The White Paper also examines a series of breast and prostate cancer cell lines that can be used in bone metastasis models.

Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com